Skye Bioscience Inc (SKYE)
Skye Bioscience Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker SKYE. The company is focused on developing molecules that modulate G-protein-coupled receptors, or GPCRs, for the potential treatment of obesity, overweight, and metabolic diseases. Its lead candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody designed to target cannabinoid receptor 1, a GPCR involved in metabolic regulation. The company is headquartered in San Diego, California. Formerly known as Emerald Bioscience, Inc., it adopted the Skye Bioscience name in January 2021.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SKYE
|
—
|
—
|
—
|
$7.33 1,021.8% Upside
|
—
|
Bargain
|
—
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
—
|
—
|
—
|
22.973 M
|
—
|
—
|
65.4%
|
—
|
—
|
—
|
